Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
We describe the feasibility and experience of the first 22 months of the Risk Evaluation and Mitigation Strategy program for prescribing mavacamten in >6000 patients with symptomatic obstructive hypertrophic cardiomyopathy. The need for temporary interruption for LVEF <50% was low, including for patients on therapy ≥1 year, with even fewer LVEF reductions associated with heart failure requiring hospitalization.
Authors
- Michael Cheung (ORCID: https://orcid.org/0000-0002-0021-3802)
- Milind Y. Desai (ORCID: https://orcid.org/0000-0003-0010-9797)
- Jeffrey J. Lockman (ORCID: https://orcid.org/0000-0002-3584-1921)
- Arnaud Bastien
- Michele Coiro
- Dewey Seto
- Matthew W. Martinez (ORCID: https://orcid.org/0000-0001-9255-4657)
- Sonia Afsari
- Niki Patel
Institutions
- Cleveland Clinic (US)
- Bristol-Myers Squibb (Germany) (DE)
- Morristown Medical Center (US)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Atlantic Health System (US)
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1161/circheartfailure.124.012441
- Citations
- 28
- Primary Topic
- Meta-analysis and systematic reviews
- Type
- article
- Field-Weighted Citation Impact
- 12.92
Funders
- Bristol-Myers Squibb